Study identifies potential epigenetic biomarker for preeclampsia

Analysis of cheek swabs taken from pregnant women revealed a potential epigenetic biomarker for preeclampsia, a potentially life-threatening condition that often leads to preterm births.

Astellas Acquires Eye-Disease Specialist Iveric for Almost $6B

Credit: FG Trade/Getty Images Astellas is acquiring Iveric Bio for approximately $5.9 billion, making Iveric a wholly-owned subsidiary. The purchase price, $40.00 per share, represents

May 1, 2023

Body dissatisfaction at age 11 may increase depression risk by age 14

Body dissatisfaction at age 11 is linked to increased risk of depression by age 14, finds a new longitudinal study led by UCL researchers.

December 14, 2023

Novartis’ radiopharma gambit; Weight loss battle plays out; Spark co-founder’s new startup; Q1 earnings highlights; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit

May 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.